Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Acquired by BlackBarn Capital Partners LP

BlackBarn Capital Partners LP raised its position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 13.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,341,871 shares of the biopharmaceutical company's stock after buying an additional 270,971 shares during the quarter. Arbutus Biopharma makes up approximately 0.4% of BlackBarn Capital Partners LP's portfolio, making the stock its 12th biggest position. BlackBarn Capital Partners LP owned approximately 1.24% of Arbutus Biopharma worth $7,658,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ABUS. State Street Corp grew its position in Arbutus Biopharma by 50.2% in the 3rd quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company's stock valued at $16,967,000 after buying an additional 1,472,652 shares during the last quarter. Rangeley Capital LLC purchased a new position in Arbutus Biopharma during the 4th quarter worth $4,771,000. JPMorgan Chase & Co. lifted its stake in shares of Arbutus Biopharma by 900.4% in the 4th quarter. JPMorgan Chase & Co. now owns 896,258 shares of the biopharmaceutical company's stock worth $2,931,000 after acquiring an additional 806,672 shares during the period. Barclays PLC boosted its holdings in shares of Arbutus Biopharma by 466.3% in the third quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company's stock valued at $1,047,000 after acquiring an additional 223,995 shares in the last quarter. Finally, Quinn Opportunity Partners LLC increased its stake in shares of Arbutus Biopharma by 72.2% during the fourth quarter. Quinn Opportunity Partners LLC now owns 404,879 shares of the biopharmaceutical company's stock worth $1,324,000 after acquiring an additional 169,747 shares during the period. 43.79% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Price Performance

Shares of ABUS stock traded down $0.05 during midday trading on Friday, reaching $3.29. 536,886 shares of the company traded hands, compared to its average volume of 989,060. The firm's 50 day simple moving average is $3.28 and its two-hundred day simple moving average is $3.45. The firm has a market cap of $629.97 million, a PE ratio of -7.65 and a beta of 1.45. Arbutus Biopharma Co. has a 1-year low of $2.63 and a 1-year high of $4.73.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $1.57 million during the quarter, compared to analysts' expectations of $2.20 million. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. As a group, research analysts anticipate that Arbutus Biopharma Co. will post -0.39 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ABUS has been the subject of a number of recent analyst reports. Chardan Capital restated a "buy" rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a research report on Friday, March 28th. HC Wainwright reissued a "buy" rating and issued a $5.00 price target on shares of Arbutus Biopharma in a report on Tuesday, January 21st. Finally, StockNews.com raised Arbutus Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, March 29th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $5.50.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.